MA29925B1 - Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds - Google Patents

Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds

Info

Publication number
MA29925B1
MA29925B1 MA30891A MA30891A MA29925B1 MA 29925 B1 MA29925 B1 MA 29925B1 MA 30891 A MA30891 A MA 30891A MA 30891 A MA30891 A MA 30891A MA 29925 B1 MA29925 B1 MA 29925B1
Authority
MA
Morocco
Prior art keywords
amide compounds
compound
pgds inhibitors
pyrimidine amide
pyrimidine
Prior art date
Application number
MA30891A
Other languages
English (en)
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA29925B1 publication Critical patent/MA29925B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (I) : dans lequel R1, R2, R3 et L1 sont comme présentement définis, une composition pharmaceutique comprenant le composé, et l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme et/ou la bronchopneumopathie chronique obstructive (COPD).
MA30891A 2005-10-04 2008-05-02 Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds MA29925B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
MA29925B1 true MA29925B1 (fr) 2008-11-03

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30891A MA29925B1 (fr) 2005-10-04 2008-05-02 Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds

Country Status (27)

Country Link
US (1) US8202863B2 (fr)
EP (1) EP1937652B1 (fr)
JP (1) JP5452925B2 (fr)
KR (1) KR101457966B1 (fr)
CN (2) CN101538246B (fr)
AR (1) AR056871A1 (fr)
AU (1) AU2006299428B2 (fr)
BR (1) BRPI0616815A2 (fr)
CA (1) CA2624749C (fr)
CR (1) CR9832A (fr)
DO (1) DOP2006000210A (fr)
EC (1) ECSP088335A (fr)
ES (1) ES2514471T3 (fr)
IL (1) IL190411A (fr)
MA (1) MA29925B1 (fr)
MY (1) MY151172A (fr)
NO (1) NO20082000L (fr)
NZ (1) NZ567208A (fr)
PE (2) PE20070589A1 (fr)
RU (1) RU2420519C2 (fr)
SG (1) SG166121A1 (fr)
TN (1) TNSN08104A1 (fr)
TW (1) TWI415839B (fr)
UA (1) UA93213C2 (fr)
UY (1) UY29840A1 (fr)
WO (1) WO2007041634A1 (fr)
ZA (1) ZA200802222B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759350B2 (en) * 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2004596A2 (fr) 2006-04-11 2008-12-24 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
CA2672373C (fr) 2006-12-19 2011-08-30 Pfizer Products Inc. Derives de la nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation dans le traitement de maladies liees aux prostaglandines d2
EP2132196A1 (fr) 2007-02-26 2009-12-16 Pfizer Products Inc. Composés hétérocycliques utiles dans le traitement de maladies et de conditions
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
AU2008310660A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
KR20100075631A (ko) 2007-10-11 2010-07-02 버텍스 파마슈티칼스 인코포레이티드 전압­개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드
WO2009049181A1 (fr) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides utiles en tant qu'inhibiteurs de canaux sodiques sensibles au voltage
WO2009064449A1 (fr) * 2007-11-13 2009-05-22 Renovis, Inc. Dérivés amide à titre de ligands de canaux ioniques et compositions pharmaceutiques et procédés d'utilisation correspondants
EP2261210B1 (fr) * 2008-02-06 2014-10-22 Msd K.K. Dérivé de sulfonylpipérazine substitué en position 3
WO2009140364A2 (fr) * 2008-05-13 2009-11-19 Cayman Chemical Company Procédés d'évaluation de la capacité de composés ou d'agents à déplacer de puissants ligands de la prostaglandine d synthase hématopoïétique
CA2725481A1 (fr) 2008-06-18 2009-12-23 Pfizer Limited Derives de nicotinamide
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
WO2010056044A2 (fr) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 Nouveau composé faisant fonction d'antagoniste du récepteur vanilloïde, isomère ou sel pharmaceutiquement acceptable dudit composé, et composition pharmaceutique le contenant
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
ES2564454T3 (es) 2009-03-09 2016-03-22 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que puede inhibir la prostaglandina D sintasa
NZ599099A (en) * 2009-10-08 2013-05-31 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
WO2011090062A1 (fr) 2010-01-22 2011-07-28 大鵬薬品工業株式会社 Composé de pipérazine ayant un effet inhibiteur des prostaglandines
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2012033069A1 (fr) 2010-09-07 2012-03-15 大鵬薬品工業株式会社 Composés de pipéridine inhibiteurs de la prostaglandine d synthase
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CN104159587A (zh) * 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
CN104926808B (zh) * 2012-08-24 2018-09-14 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (fr) * 2016-03-14 2017-09-21 Emory University Dérivés amide-sulfamide, compositions et utilisations associées à l'inhibition de cxcr4
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
TW201908311A (zh) 2017-06-13 2019-03-01 英商葛蘭素史克智慧財產發展有限公司 化合物
WO2019084529A1 (fr) * 2017-10-29 2019-05-02 China Medical University Inhibiteurs d'adam9 et utilisations de ceux-ci
JP2021506811A (ja) 2017-12-13 2021-02-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈ−ｐｇｄｓの阻害剤として作用する縮合ピリジン
MX2020009887A (es) * 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
CN112969698A (zh) 2018-11-08 2021-06-15 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
BR112022023025A2 (pt) * 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
CN115667259B (zh) 2020-06-19 2025-06-17 佐藤制药株式会社 抑制h-pgds的稠环化合物
US12331046B2 (en) * 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2023113023A1 (fr) 2021-12-17 2023-06-22 佐藤製薬株式会社 Dérivé d'azaindole inhibant h-pgds
CA3245288A1 (fr) * 2022-02-28 2025-06-13 Shionogi & Co., Ltd. Composé d'indazole et son utilisation pharmaceutique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1218336A2 (fr) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
JP4595542B2 (ja) * 2002-07-30 2010-12-08 萬有製薬株式会社 ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
EP1606289B1 (fr) * 2003-02-14 2009-12-02 Glaxo Group Limited Derives de carboxamide
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
MXPA06003949A (es) * 2003-10-07 2006-06-27 Renovis Inc Compuestos amida como ligandos del canal de ion y su uso.
CA2553968A1 (fr) * 2004-01-23 2005-08-11 Amgen Inc. Ligands du recepteur vanilloide et leur application au traitement des douleurs inflammatoires et neuropathiques
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
EP1937652A1 (fr) 2008-07-02
RU2420519C2 (ru) 2011-06-10
ECSP088335A (es) 2008-05-30
AU2006299428B2 (en) 2012-04-26
IL190411A0 (en) 2008-11-03
AU2006299428A1 (en) 2007-04-12
SG166121A1 (en) 2010-11-29
JP2009510170A (ja) 2009-03-12
KR101457966B1 (ko) 2014-11-04
MY151172A (en) 2014-04-30
CR9832A (es) 2008-06-18
CN101538246A (zh) 2009-09-23
IL190411A (en) 2013-09-30
CA2624749A1 (fr) 2007-04-12
ES2514471T3 (es) 2014-10-28
CN101282943A (zh) 2008-10-08
TWI415839B (zh) 2013-11-21
US8202863B2 (en) 2012-06-19
BRPI0616815A2 (pt) 2011-07-05
DOP2006000210A (es) 2007-06-15
WO2007041634A1 (fr) 2007-04-12
EP1937652B1 (fr) 2014-07-30
TW200812977A (en) 2008-03-16
UY29840A1 (es) 2007-05-31
RU2008117170A (ru) 2009-11-10
PE20110118A1 (es) 2011-03-08
KR20080050611A (ko) 2008-06-09
ZA200802222B (en) 2009-09-30
UA93213C2 (en) 2011-01-25
JP5452925B2 (ja) 2014-03-26
NZ567208A (en) 2011-03-31
US20080227782A1 (en) 2008-09-18
PE20070589A1 (es) 2007-06-22
NO20082000L (no) 2008-06-09
CA2624749C (fr) 2011-08-16
CN101538246B (zh) 2014-07-16
TNSN08104A1 (en) 2009-07-14
AR056871A1 (es) 2007-10-31

Similar Documents

Publication Publication Date Title
MA29925B1 (fr) Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds
MA31326B1 (fr) Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
MA35285B1 (fr) Indazoles
NO20084005L (no) Aminderivater
WO2005121130A3 (fr) Composes pour le traitement de troubles inflammatoires
PL357555A1 (en) Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
DE602006013493D1 (de) Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
MA32615B1 (fr) Inhibiteurs de cmet
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
MA33725B1 (fr) Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds
MA31373B1 (fr) Composes amino-heterocycliques
WO2004033431A3 (fr) Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
EP1423111A4 (fr) Composes de liaison au recepteur nucleaire fxr nr1h4
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
MA32798B1 (fr) Acides naphtylacétiques
WO2007146349A3 (fr) Antagonistes du récepteur du cgrp
MA29267B1 (fr) Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension.
WO2006002434A3 (fr) Nouveaux indazole carboxamides et leur utilisation
WO2006055434A3 (fr) Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer
GB0407025D0 (en) Novel compounds
WO2005090287A3 (fr) Composes convenant pour le traitement de maladies
TN2009000205A1 (fr) Analogues de pyrazoles